API
< Back to all clusters
[HEALTH] · Chile · 2 sources

started · updated

Chile proposes regulatory changes for biosimilar drug interchangeability

The Chilean Ministry of Health has submitted a decree to the Comptroller General of the Republic to modify the Regulation of the National Control System for Pharmaceutical Products for Human Use. The proposed changes aim to incorporate biosimilars into the regulatory framework for demonstrating bioequivalence and interchangeability under Article 101 of the Sanitary Code.

If implemented, this would allow for the exchange of prescribed biological medicines for certified biosimilars at pharmacies, a practice that is generally exceptional in other jurisdictions. While the European Medicines Agency recognizes biosimilars as safe and effective, individual member states maintain cautious approaches to pharmacy-level substitution. Similarly, in the United States, the FDA designates interchangeability on a product-by-product basis.

Entities

Chile · Comptroller General of the Republic · European Medicines Agency · FDA · Ministry of Health